Precision immunotherapies for systemic lupus erythematosus: From pathogenic targets to translational horizons - PubMed
a day ago
- #Autoantibodies
- #Precision immunotherapy
- #Systemic lupus erythematosus
- Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by aberrant B-cell activation, autoantibody production, and dysregulated cytokine signaling.
- Conventional immunosuppressants have limitations in specificity, toxicity, and long-term disease control.
- Precision immunotherapies are emerging, targeting immune-cell surface antigens (e.g., BAFF/APRIL antagonism, CD19-directed CAR-T), cytokine networks (e.g., IFN-I blockade, JAK/STAT inhibition), and autoantibody-focused approaches (e.g., mimetic peptides, CAAR-T cells).
- AI and machine learning are playing a role in addressing patient heterogeneity, molecular endotyping, and predictive therapeutic modeling.
- The review outlines a roadmap for clinical implementation of these therapies over the next 5-10 years.